Investigating the efficacy of high dose of glucocorticoid in patients with moderate to severe pneumonia related to COVID-19

Bagheiat-allah University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新: 2020年5月18日

试验速览

暂无简介。

•Confirmed diagnosis of COVID-19, with either lung CT-Scan result, which is typical for COVID-19 pulmonary involvement,or RT-PCR confirmation.
•The patient has written consciously and freely consent to participate in the study;
•The patient has moderate to severe Corona-Virus associated pneumonia;
•In the first 48 hours of hospitalization, the patient did not show an improving trend;
•In the first 48 hours after his/her inclusion into this study, there is no possibility of discharge from the patient's hospital;

•History of hypersensitivity reaction to glucocorticoids;
•Recent hospitalization and treatment history due to COVID-19;
•Receive antiviral drugs before including into this study, such as: Hydroxychloroquine, Kaletra, Ribavirin, Oseltamivir;
•Receiving Methylprednisolone pulse before including into this study;
•Uncontrolled severe chronic illnesses, including heart failure, kidney failure, liver failure, active cancer (history of chemotherapy within recent month), diabetes;
•Receiving immunosuppressing /immunomodulating agents, such as systemic glucocorticoids.

发起方

Bagheiat-allah University of Medical Sciences